LifeSci Capital analyst Patrick Dolezal reiterated an Outperform rating and $9 price target on Rocket Pharmaceuticals (RCKT) after the company announced approval of Kresladi in ultra-rare disease leukocyte adhesion deficiency type 1, along with reception of a rare pediatric disease priority review voucher that the company intends to monetize. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100M-$200M. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company’s cardiac gene-therapy pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
- Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
- Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
- Video: Unity rises after better-than-expected pre-announcement
- Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy